Loading
A phase 2 trial of single dose of CNCT19 in non-Hodgkin lymphoma, run by Juventas Cell Therapy Ltd., now recruiting.
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT04586478 by Juventas Cell Therapy Ltd., with 60 participants planned, started 2020-10-26 and due to reach its primary completion in 2024-03-30. Interventions recorded: single dose of CNCT19.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Juventas Cell Therapy, Inaticabtagene autoleucel, CAR-T cell therapy and the tag pipeline.
Shares Juventas Cell Therapy, Inaticabtagene autoleucel, CAR-T cell therapy and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/